Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Liabilities and Shareholders Equity (2022 - 2025)

TriSalus Life Sciences' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $35.3 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 47.39% year-over-year to $35.3 million; the TTM value through Dec 2025 reached $141.7 million, up 39.27%, while the annual FY2025 figure was $35.3 million, 47.39% up from the prior year.
  • Liabilities and Shareholders Equity reached $35.3 million in Q4 2025 per TLSIW's latest filing, down from $36.5 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $251.3 million in Q3 2022 to a low of $12.2 million in Q2 2023.
  • Average Liabilities and Shareholders Equity over 4 years is $69.3 million, with a median of $30.5 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 95.12% in 2023, then surged 165.01% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $22.0 million in 2022, then rose by 11.83% to $24.6 million in 2023, then dropped by 2.55% to $24.0 million in 2024, then skyrocketed by 47.39% to $35.3 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Liabilities and Shareholders Equity are $35.3 million (Q4 2025), $36.5 million (Q3 2025), and $41.3 million (Q2 2025).